Fulphila is a biosimilar medication containing pegfilgrastim, a recombinant human granulocyte colony-stimulating factor (G-CSF). It is used to stimulate the production of neutrophils, helping to reduce the risk of infection in patients undergoing certain cancer treatments.
How it Works
Pegfilgrastim is a synthetic form of a natural substance in the body that stimulates the bone marrow to produce more neutrophils, which are essential for fighting infections.
Fulphila provides a reliable and effective solution for patients undergoing chemotherapy who are at risk of neutropenia. By stimulating neutrophil production, it helps reduce the risk of infections, contributing to a safer cancer treatment experience.
*Disclaimer: The information provided here is not intended to endorse any specific medication, and it is essential to adhere to the regulations and guidelines set forth by healthcare authorities. Self-medication or the use of prescription medications without professional guidance can lead to serious health risks. Always consult with qualified healthcare professionals for personalized advice and follow recommended medical guidelines.*